ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02975102
Recruitment Status : Recruiting
First Posted : November 29, 2016
Last Update Posted : November 14, 2017
Sponsor:
Information provided by (Responsible Party):
Laboratoire Chauvin

Brief Summary:
The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-101 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day.

Condition or disease Intervention/treatment Phase
Dry Eye Device: CBL-101 Eye Drops Device: Vismed® Multi Not Applicable

Detailed Description:
Study duration will be approximately 15 weeks from screening to the last visit. Subjects will visit the clinic approximately 5 times.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
Actual Study Start Date : March 1, 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : May 2018

Arm Intervention/treatment
Experimental: CBL-101 Eye Drops
The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
Device: CBL-101 Eye Drops
CBL-101 Eye Drops 3 to 6 times per day for 3 months.

Active Comparator: Vismed® Multi
The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
Device: Vismed® Multi
Vismed® Multi 3 to 6 times per day for 3 months.




Primary Outcome Measures :
  1. Ocular surface fluorescein staining score at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye in ocular surface fluorescein staining score according to a scale from 0 to 15, combining corneal, nasal and temporal bulbar conjunctival fluorescein staining, each graded 0 to 5, according to the Oxford Scheme.


Secondary Outcome Measures :
  1. Total ocular surface fluorescein staining score at Visit 3 [ Time Frame: Baseline (Day 0), Visit 3 (Day 7) ]
    Mean change from baseline in the study eye

  2. Total ocular surface fluorescein staining score at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Mean change from baseline in the study eye

  3. Corneal fluorescein staining score at Visit 3 [ Time Frame: Baseline (Day 0), Visit 3 (Day 7) ]
    Mean change from baseline in the study eye

  4. Corneal fluorescein staining score at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    Mean change from baseline in the study eye

  5. Corneal fluorescein staining score at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Mean change from baseline in the study eye

  6. Nasal conjunctival fluorescein staining score at Visit 3 [ Time Frame: Baseline (Day 0), Visit 3 (Day 7) ]
    Mean change from baseline in the study eye

  7. Nasal conjunctival fluorescein staining score at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    Mean change from baseline in the study eye

  8. Nasal conjunctival fluorescein staining score at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Mean change from baseline in the study eye

  9. Temporal conjunctival fluorescein staining score at Visit 3 [ Time Frame: Baseline (Day 0), Visit 3 (Day 7) ]
    Mean change from baseline in the study eye

  10. Temporal conjunctival fluorescein staining score at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    Mean change from baseline in the study eye

  11. Temporal conjunctival fluorescein staining score at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Mean change from baseline in the study eye

  12. Tear Film Break Up Time (TFBUT) at Visit 3 [ Time Frame: Baseline (Day 0), Visit 3 (day 7) ]
    Mean change from baseline in the study eye

  13. TFBUT at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    Mean change from baseline in the study eye

  14. TFBUT at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Mean change from baseline in the study eye

  15. Ocular Surface Disease-Quality of Life (OSD-QoL®) at Visit 5 [ Time Frame: Baseline (Day 0), Visit 5 (Day 90) ]
    Evolution from baseline of OSD-QoL® questionnaire scores for all 7 dimensions: Daily Activities, Handicap and Work Difficulties, Giving up Make-up, Acknowledgement, Acceptance, Fear for the Future, Emotional Well-Being, and Global Question.

  16. Global sum score of dry eye symptoms at Visit 4 [ Time Frame: Baseline, Visit 4 (Day 28) ]
    Mean change from baseline in the global sum score of dry eye symptoms: sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light, each graded from 0 to 4

  17. Global sum score of dry eye symptoms at Visit 5 [ Time Frame: Baseline, Visit 5 (Day 90) ]
    Mean change from baseline in the global sum score of dry eye symptoms: sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light, each graded from 0 to 4

  18. Volume of tear fluid secretion as assessed by the unanaesthetized Schirmer test at Visit 4 [ Time Frame: Baseline (Day 0), Visit 4 (Day 28) ]
    Mean change from baseline in the study eye



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed and with the capacity to provide voluntary informed consent
  2. Subjects must be able to read, understand, and provide written informed consent on the Ethics Committee (EC) approved ICF
  3. Subjects who are able and willing to comply with all treatment and follow-up, study procedures
  4. Subjects who have been using tear substitutes for at least 3 months prior to inclusion, and who will use multidose preservative-free ART (Aqualarm U.P. povidone 2% eye drops in 10 mL bottles) up to 6 times a day for at least 2 weeks immediately prior to randomization
  5. Subjects with a score ≥ 1 for at least 2 out of the 7 following symptoms (rated 0 to 4): sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light
  6. Subjects with at least 1 eye with the following signs of keratoconjunctivitis sicca :

    • Tear break-up time of ≤ 10sec (mean of 3 measurements) at both screening visit and inclusion visit
    • Total ocular surface staining score ≥ 4 and ≤ 9 at both screening visit and inclusion visit. This assessment combines corneal, nasal and temporal bulbar conjunctival fluorescein staining, each graded 0-5 according to the Oxford Scheme
  7. Subjects who have a decimal visual acuity (VA) with habitual correction equal to or better than 0.1 (Monoyer chart) in both eyes
  8. Subjects with no systemic treatment or who are receiving stable systemic treatment (unchanged for 1 month or longer)
  9. Female subjects who are not of childbearing potential or who have a negative urine pregnancy test result at screening

Exclusion Criteria:

Ocular Exclusion Criteria

  1. Subjects with moderate or severe blepharitis defined by at least moderate (a score of ≥ 2 from a range of 0 to 3) eyelid margin hyperemia or moderate eyelid swelling or both and at least moderate eyelid debris or moderate plugging of meibomian glands or both
  2. Subjects who have severe ocular dryness accompanied by one of the following:

    • Lid abnormality (except mild blepharitis)
    • Corneal disease
    • Ocular surface metaplasia
    • Filamentary keratitis
    • Corneal neovascularization
  3. Subjects who currently wear contact lenses or have worn contact lenses within 90 days prior to study start
  4. Subjects who have received ocular surgery, including laser surgery, in either eye within 180 days prior to study start
  5. Subjects with a history of ocular trauma, non-dry eye ocular inflammation, or ocular infection within 90 days prior to study start
  6. Subjects with a history of ocular allergic disease or ocular herpes within 1 year prior to study start
  7. Subjects with a history of any inflammatory ulcerative keratitis, recurrent corneal erosion, or uveitis

    Treatment Exclusion Criteria

  8. Subjects with known hypersensitivity or contraindications to any of the ingredients in the test or comparator products or ART
  9. Subjects with initiation of, or changes to, concomitant medication that could affect dry eye within 30 days prior to Visit 1 (Screening) or with planned initiation or changes of such medications during the study
  10. Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start
  11. Subjects expected to receive ocular therapy during the study
  12. Subjects treated with topical ocular steroidal or non-steroidal antiinflammatory medication within 30 days prior to study start
  13. Subjects expected to receive ocular therapy with immunosuppressants (e.g. cyclosporine) during the study or who have used ocular immunosuppressants within 90 days prior to study start
  14. Subjects who have received occlusion therapy with lacrimal or punctum plugs within 90 days prior to study start

    General Exclusion Criteria

  15. Female subjects who are sexually active and who do not fall into 1 of the following categories:

    • Post-menopausal
    • Surgically sterile
    • Using one of the following birth control methods throughout the duration of the study: Intrauterine device (at least for 14 days prior to study start) or Barrier method (condom or diaphragm) with spermicide (at least for 14 days prior to study start) or Hormonal contraception (same dose and same formulation for at least 6 months)
  16. Females who are breastfeeding
  17. Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and, or during the period of study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02975102


Contacts
Contact: Raphaele Siou Mermet, MD +33619530690 raphaele.siou-mermet@bausch.com

Locations
France
Pr Mortemousque private office Recruiting
Bordeaux, France, 33000
Contact: Pr Mortemousque         
Sponsors and Collaborators
Laboratoire Chauvin
Investigators
Study Director: Raphaele Siou Mermet, MD Laboratoire Chauvin

Responsible Party: Laboratoire Chauvin
ClinicalTrials.gov Identifier: NCT02975102     History of Changes
Other Study ID Numbers: 2016-A01121-50
First Posted: November 29, 2016    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Ophthalmic Solutions
Pharmaceutical Solutions